Information Provided By: 
Fly News Breaks for February 22, 2019
FIT
Feb 22, 2019 | 07:18 EDT
Wedbush analyst Michael Pachter downgraded Fitbit to Neutral from Outperform, as shares have reached his $6.50 price target with no new available information on the MedTech opportunity. In a research note to investors, Pachter says he thinks what is currently known about the MedTech opportunity is fully priced into Fitbit's share price, and will step to the sidelines until he knows more.
News For FIT From the Last 2 Days
There are no results for your query FIT
